Outcome of hospitalized patients with hematological malignancies and COVID-19 infection in a large urban healthcare trust in the United Kingdom

Garnett, Catherine; Foldes, David; Bailey, Chris; Nesr, George; Hui, Tracy; Hinton, Richard H.; Gurung, Kamala; Phillips, James D.; Saleem, Zahbia; Koshy, Rincy; Aduwa, Elvis; Colis, Marife; Bimolah, Ravi; Katsomitrou, Vaitsa; Arami, Siamak; Kagdi, Huseini

doi:10.1080/10428194.2020.1838506

Cited by 8 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, in previously published reports focusing on the outcome of patients with hematological malignancies admitted for COVID-19, either none, 17,18 or only a minority, 19,20 of patients had CML.…”

mentioning

confidence: 61%

“…The mortality rates in our cohort, both of the total cohort and of hospitalized patients (1/3, 33%) was less than other reports including patients with various hematological malignancies from the United Kingdom, 21 including our center. 18 In our cohort, all the patients who were receiving imatinib whilst COVID-19 positive recovered. This contrasts the finding of a strong association between mortality and imatinib by Rea et al, 10 and further supports their explanation that this association was confounded by the link between imatinib and old age.…”

mentioning

confidence: 84%

See 1 more Smart Citation

Outcome of COVID‐19 in patients with chronic myeloid leukemia: A single centre UK experience

Nesr

Saleem

Arami

2021

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) has a wide spectrum of clinical presentations, ranging from asymptomatic infection to critical disease requiring intensive care admission and ventilatory support, 1 with a dysregulated immune response, or the cytokine storm, being implicated in the causation of the latter. 2 Determining which part of this spectrum a patient falls in is dependent on a number of factors, amongst which comorbidities, including hematological malignancies, are a major contributor.Available data show variable effects of hematological malignancies on the outcome of patients with COVID-19 based on the disease and the treatment received, including a "protective" effect from severe COVID-19 due to the weakened immune response in some patients. 3 Most of the reports about patients with chronic myeloid leukemia (CML) and COVID-19 described a mild disease course with recovery, 4-10 except for one case report. 11 One possible explanation is the antiviral effect of tyrosine kinase inhibitors (TKIs) through off-target Abl kinase inhibitor which blocks viral entry into host cells, 12 upregulating "antiviral" genes, and decreasing the expression of genes with "proviral" action. 13 In fact, several clinical trials are currently looking into the use of imatinib to treat patients with COVID-19. 14 On the other hand, patients with CML not achieving a complete hematological response, and those in advanced phase disease who did not achieve a complete cytogenetic or a major molecular response had an increased risk of developing COVID-19. 9Herein, we report a case series of nine patients with chronic phase (CP)-CML who had COVID-19 in the period between December 2020 and March 2021 and present their outcomes. All patients had their CML management under the Haematology Department in Northwick Park Hospital, a part of the London North West University Healthcare NHS Trust. COVID-19 diagnosis was confirmed by a positive polymerase chain reaction for severe acute respiratory syndrome coronavirus 2 on a nasopharyngeal swab for all patients. COVID-19 severity was assessed according to National Institute for Health and Care Excellence and World Health Organization guidelines. 15 Patients' data were retrospectively collected from their medical records. Statistical Package for Social Sciences software, version 27 (SPSS; IBM Corp.) was used for statistical analysis.Median and range were used to summarize nonparametric quantitative data. Fisher exact test was used to compare qualitative data, and Mann-Whitney U test to compare medians between groups. A

show abstract

mentioning

confidence: 61%

mentioning

confidence: 84%

Outcome of COVID‐19 in patients with chronic myeloid leukemia: A single centre UK experience

Nesr

Saleem

Arami

2021

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Our study confirmed this higher rate. Catherine Garnett et al [ 31 ] reported 56% of mortality in their series of 32 patients with hematologic cancer. This rate was reported as 37% in the series of Mehta V et al [ 32 ] In the systematic review and meta-analysis of Vijenthira A et al [ 33 ] in-hospital mortality was 34% among 3377 patients with hematologic cancer patients ≥60 year-old had a higher mortality (RR, 1.82; 95% CI, 1.45–2.27; N = 1169).…”

Section: Discussionmentioning

confidence: 99%

COVID 19 and febrile neutropenia: Case report and systematic review

Kaya¹,

Dilek²,

Özaras³

et al. 2022

Travel Medicine and Infectious Disease

View full text Add to dashboard Cite

“…While these familial factors may suggest a genetic cause for this disease, research also suggests that an abnormal immune response to infection may play a role in the pathogenesis of HL. Epidemiologic and serologic studies have implicated Epstein-Barr virus (EBV) in the etiology of HL and the EBV genome was detected in tumor specimens from patients with HL [10].…”

Section: Introductionmentioning

confidence: 99%

Complete remission of Hodgkin Lymphoma after a concurrent infection with COVID-19: systematic review and meta-analysis

Yousif¹

2022

MMJ

View full text Add to dashboard Cite

Through December 2019, novel coronavirus (SARS-CoV-2) pneumonia (COVID-19) was reported in Wuhan and has since rapidly spread throughout China. Hodgkin lymphoma represents a heterogeneous hematological malignancy, which is characterized by immunosuppression. There are no clearly defined risk factors for the development of this disease and the cause of remains unknown. Factors shown to be associated with Hodgkin include familial factors, viral exposures, and immune suppression. An electronic search was performed to identify all studies reporting on the management of Hodgkin lymphoma patients during the COVID-19 pandemic. The PubMed/MEDLINE database was searched on October 30th, 2019, to January 30th. 2022. The search strategy was SARS-CoV-2 or COVID-19 and Hodgkin lymphoma. We aimed to clarify the clinical outcome of COVID-19 in patients with Hodgkin lymphoma through systematic review and meta-analysis.

show abstract

Outcome of hospitalized patients with hematological malignancies and COVID-19 infection in a large urban healthcare trust in the United Kingdom

Cited by 8 publications

References 8 publications

Outcome of COVID‐19 in patients with chronic myeloid leukemia: A single centre UK experience

Outcome of COVID‐19 in patients with chronic myeloid leukemia: A single centre UK experience

COVID 19 and febrile neutropenia: Case report and systematic review

Complete remission of Hodgkin Lymphoma after a concurrent infection with COVID-19: systematic review and meta-analysis

Contact Info

Product

Resources

About